Whereas there are several examples in Japanese Pharmaceutical Industry were orphan drugs with a clear indication have been developed, pricing schemes are still not finally concluded with the National Health Insurance scheme, and the present discussion of a 20 % higher price might not be enough to cover additional costs

Nikkei Biotech, February 12, 2013